Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications.
Europe
medicine shortage
mitigation strategy
risk assessment
substitution
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
10
2019
accepted:
10
03
2020
entrez:
11
4
2020
pubmed:
11
4
2020
medline:
11
4
2020
Statut:
epublish
Résumé
While medicine shortages are complex, their mitigation is more of a challenge. Prospective risk assessment as a means to mitigate possible shortages, has yet to be applied equally across healthcare settings. The aims of this study have been to: 1) gain insight into risk-prevention against possible medicine shortages among healthcare experts; 2) review existing strategies for minimizing patient-health risks through applied risk assessment; and 3) learn from experiences related to application in practice. A semi-structured questionnaire focusing on medicine shortages was distributed electronically to members of the European Cooperation in Science and Technology (COST) Action 15105 (28 member countries) and to hospital pharmacists of the European Association of Hospital Pharmacists (EAHP) (including associated healthcare professionals). Their answers were subjected to both qualitative and quantitative analysis (Microsoft Office Excel 2010 and IBM SPSS Statistics The participants (61.7%) are aware of the use of risk assessment procedures as a coping strategy for medicine shortages, and named the particular risk assessment procedure they are familiar with failure mode and effect analysis (FMEA) (26.4%), root cause analysis (RCA) (23.5%), the healthcare FMEA (HFMEA) (14.7%), and the hazard analysis and critical control point (HACCP) (14.7%). Only 29.4% report risk assessment as integrated into mitigation strategy protocols. Risk assessment is typically conducted within multidisciplinary teams (35.3%). Whereas 14.7% participants were aware of legislation stipulating risk assessment implementation in shortages, 88.2% claimed not to have reported their findings to their respective official institutions. 85.3% consider risk assessment a useful mitigation strategy. The study indicates a lack of systematically organized tools used to prospectively analyze clinical as well as operationalized risk stemming from medicine shortages in healthcare. There is also a lack of legal instruments and sufficient data confirming the necessity and usefulness of risk assessment in mitigating medicine shortages in Europe.
Identifiants
pubmed: 32273845
doi: 10.3389/fphar.2020.00357
pmc: PMC7114887
doi:
Types de publication
Journal Article
Langues
eng
Pagination
357Informations de copyright
Copyright © 2020 Miljković, Godman, Kovačević, Polidori, Tzimis, Hoppe-Tichy, Saar, Antofie, Horvath, De Rijdt, Vida, Kkolou, Preece, Tubić, Peppard, Martinez, Yubero, Haddad, Rajinac, Zelić, Jenzer, Tartar, Gitler, Jeske, Davidescu, Beraud, Kuruc-Poje, Haag, Fischer, Sviestina, Ljubojević, Markestad, Vujić-Aleksić, Nežić, Crkvenčić, Linnolahti, Ašanin, Duborija-Kovačević, Bochenek, Huys and Miljković.
Références
J Eval Clin Pract. 2015 Aug;21(4):549-59
pubmed: 25847021
J Oncol Pharm Pract. 2020 Apr;26(3):666-679
pubmed: 31475881
Hosp Pharm. 2015 Apr;50(4):279-86
pubmed: 26448658
Am J Health Syst Pharm. 2018 Nov 1;75(21):1742-1750
pubmed: 30061155
Am J Health Syst Pharm. 2014 Apr 1;71(7):571-8
pubmed: 24644117
P T. 2011 Nov;36(11):740-57
pubmed: 22346307
Z Evid Fortbild Qual Gesundhwes. 2016;114:28-38
pubmed: 27566267
PLoS One. 2015 Mar 16;10(3):e0119322
pubmed: 25775406
Clin Infect Dis. 2005 Oct 1;41(7):1014-9
pubmed: 16142668
Front Pharmacol. 2014 Oct 08;5:219
pubmed: 25339902
Am J Health Syst Pharm. 2011 Oct 1;68(19):1811-9
pubmed: 21930639
Front Pharmacol. 2019 Jul 19;10:763
pubmed: 31379565
PLoS One. 2019 May 3;14(5):e0215837
pubmed: 31050671
Front Pharmacol. 2018 Jan 18;8:942
pubmed: 29403372
Eur J Hosp Pharm. 2018 Sep;25(5):237-244
pubmed: 31157033
Ann Pharm Fr. 2019 May;77(3):205-211
pubmed: 30670298
Front Pharmacol. 2015 Oct 30;6:253
pubmed: 26578963
Appl Health Econ Health Policy. 2017 Aug;15(4):441-445
pubmed: 27480539
Am J Health Syst Pharm. 2018 Jun 1;75(11):816-820
pubmed: 29802115
Isr J Health Policy Res. 2017 Apr 3;6:17
pubmed: 28392910
Eur J Hosp Pharm. 2019 Mar;26(2):60-65
pubmed: 31157101
Bull World Health Organ. 2012 Mar 1;90(3):158-158A
pubmed: 22461706
Drug Saf. 2014 Jan;37(1):33-42
pubmed: 24357107
Jt Comm J Qual Improv. 2002 May;28(5):248-67, 209
pubmed: 12053459
BMC Med. 2014 Jun 13;12:98
pubmed: 24927744
J Clin Epidemiol. 2004 Sep;57(9):973-7
pubmed: 15504640
Can J Cardiol. 2017 Feb;33(2):283-286
pubmed: 27923583
Clin Chim Acta. 2009 Jun;404(1):75-8
pubmed: 19298799
Qual Saf Health Care. 2005 Apr;14(2):93-8
pubmed: 15805453
BMC Med. 2016 Sep 29;14(1):124
pubmed: 27683105